Skip to main content
Erschienen in: Supportive Care in Cancer 3/2016

01.03.2016 | Original Article

Contrast-induced nephropathy in patients with active cancer undergoing contrast-enhanced computed tomography

verfasst von: Seok-In Hong, Shin Ahn, Yoon-Seon Lee, Won Young Kim, Kyung Soo Lim, Jae Ho Lee, Jae-Lyun Lee

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study was performed to measure the incidence and identify potential predictors of contrast-induced nephropathy (CIN) in cancer patients without chronic kidney disease and with normal or near-normal baseline serum creatinine measures who underwent contrast-enhanced computed tomography (CECT). Severity of CIN was reported based on the RIFLE (risk, injury, failure, loss of kidney function, and end-stage renal disease) classification of acute kidney injury.

Methods

A retrospective analysis was performed on 820 cancer patients who presented at our emergency department from October 2014 to March 2015. CIN was defined as an increase in creatinine concentration of ≥0.5 mg/dL or ≥25 % above baseline that occurred 48 to 72 h after CECT.

Results

The incidence of CIN was 8.0 %. Serial CT examination [odds ratio (OR) 4.09; 95 % confidence interval (CI) 1.34–12.56], hypotension before the CT scan (OR 3.95; 95 % CI 1.77–8.83), liver cirrhosis (OR 2.82; 95 % CI 1.06–7.55), BUN/creatinine >20 (OR 2.54; 95 % CI 1.44–4.46), and peritoneal carcinomatosis (OR 1.75; 95 % CI 1.01–3.00) were independently associated with CIN. Of 66 CIN patients, 44 met any of the severity criteria of the RIFLE classification. Five of these patients died during hospitalization but only one death was related to renal failure.

Conclusions

Even when the baseline serum creatinine is ≤1.5 mg/dL, a significant portion of cancer patients are still at risk of CIN. Consecutive CECT examinations, hypotension before CT, liver cirrhosis, dehydration, and peritoneal carcinomatosis seem to predispose patients to CIN.
Literatur
3.
Zurück zum Zitat Traub SJ, Kellum JA, Tang A, Cataldo L, Kancharla A, Shapiro NI (2013) Risk factors for radiocontrast nephropathy after emergency department contrast-enhanced computerized tomography. Acad Emerg Med 20(1):40–45. doi:10.1111/acem.12059 CrossRefPubMed Traub SJ, Kellum JA, Tang A, Cataldo L, Kancharla A, Shapiro NI (2013) Risk factors for radiocontrast nephropathy after emergency department contrast-enhanced computerized tomography. Acad Emerg Med 20(1):40–45. doi:10.​1111/​acem.​12059 CrossRefPubMed
5.
Zurück zum Zitat Launay-Vacher V, Oudard S, Janus N et al (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 110(6):1376–1384. doi:10.1002/cncr.22904 CrossRefPubMed Launay-Vacher V, Oudard S, Janus N et al (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 110(6):1376–1384. doi:10.​1002/​cncr.​22904 CrossRefPubMed
6.
Zurück zum Zitat Dogan E, Izmirli M, Ceylan K et al (2005) Incidence of renal insufficiency in cancer patients. Adv Ther 22(4):357–362CrossRefPubMed Dogan E, Izmirli M, Ceylan K et al (2005) Incidence of renal insufficiency in cancer patients. Adv Ther 22(4):357–362CrossRefPubMed
7.
8.
Zurück zum Zitat Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative w (2004) Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8(4):R204–212. doi:10.1186/cc2872 CrossRef Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative w (2004) Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8(4):R204–212. doi:10.​1186/​cc2872 CrossRef
9.
Zurück zum Zitat Ashley JB, Millward SF (2003) Contrast agent-induced nephropathy: a simple way to identify patients with preexisting renal insufficiency. Am J Roentgenol 181(2):451–454CrossRef Ashley JB, Millward SF (2003) Contrast agent-induced nephropathy: a simple way to identify patients with preexisting renal insufficiency. Am J Roentgenol 181(2):451–454CrossRef
12.
Zurück zum Zitat Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461–470CrossRefPubMed Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461–470CrossRefPubMed
13.
Zurück zum Zitat Morgan DB, Carver ME, Payne RB (1977) Plasma creatinine and urea: creatinine ratio in patients with raised plasma urea. Br Med J 2(6092):929–932PubMedCentralCrossRefPubMed Morgan DB, Carver ME, Payne RB (1977) Plasma creatinine and urea: creatinine ratio in patients with raised plasma urea. Br Med J 2(6092):929–932PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Moos SI, van Vemde DN, Stoker J, Bipat S (2013) Contrast induced nephropathy in patients undergoing intravenous (IV) contrast enhanced computed tomography (CECT) and the relationship with risk factors: a meta-analysis. Eur J Radiol 82(9):e387–399. doi:10.1016/j.ejrad.2013.04.029 CrossRefPubMed Moos SI, van Vemde DN, Stoker J, Bipat S (2013) Contrast induced nephropathy in patients undergoing intravenous (IV) contrast enhanced computed tomography (CECT) and the relationship with risk factors: a meta-analysis. Eur J Radiol 82(9):e387–399. doi:10.​1016/​j.​ejrad.​2013.​04.​029 CrossRefPubMed
18.
Zurück zum Zitat Poletti PA, Saudan P, Platon A et al (2007) I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol 189(3):687–692. doi:10.2214/AJR.07.2356 CrossRefPubMed Poletti PA, Saudan P, Platon A et al (2007) I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol 189(3):687–692. doi:10.​2214/​AJR.​07.​2356 CrossRefPubMed
20.
Zurück zum Zitat Cheruvu B, Henning K, Mulligan J et al (2007) Iodixanol: risk of subsequent contrast nephropathy in cancer patients with underlying renal insufficiency undergoing diagnostic computed tomography examinations. J Comput Assist Tomogr 31(4):493–498. doi:10.1097/rct.0b013e31802e29d9 CrossRefPubMed Cheruvu B, Henning K, Mulligan J et al (2007) Iodixanol: risk of subsequent contrast nephropathy in cancer patients with underlying renal insufficiency undergoing diagnostic computed tomography examinations. J Comput Assist Tomogr 31(4):493–498. doi:10.​1097/​rct.​0b013e31802e29d9​ CrossRefPubMed
21.
Zurück zum Zitat Carstensen M, Keer D, Rempel J, Jeon P, Barrett B (2012) Prevalence of risk factors for contrast-induced nephrotoxicity in outpatients undergoing intravenous contrast-enhanced computed tomography studies. Can Assoc Radiol J 63(3):177–182. doi:10.1016/j.carj.2010.12.004 CrossRefPubMed Carstensen M, Keer D, Rempel J, Jeon P, Barrett B (2012) Prevalence of risk factors for contrast-induced nephrotoxicity in outpatients undergoing intravenous contrast-enhanced computed tomography studies. Can Assoc Radiol J 63(3):177–182. doi:10.​1016/​j.​carj.​2010.​12.​004 CrossRefPubMed
25.
Zurück zum Zitat Lodhia N, Kader M, Mayes T, Mantry P, Maliakkal B (2009) Risk of contrast-induced nephropathy in hospitalized patients with cirrhosis. World J Gastroenterol 15(12):1459–1464PubMedCentralCrossRefPubMed Lodhia N, Kader M, Mayes T, Mantry P, Maliakkal B (2009) Risk of contrast-induced nephropathy in hospitalized patients with cirrhosis. World J Gastroenterol 15(12):1459–1464PubMedCentralCrossRefPubMed
29.
Zurück zum Zitat Hoste EA, Lameire NH, Vanholder RC, Benoit DD, Decruyenaere JM, Colardyn FA (2003) Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol 14(4):1022–1030CrossRefPubMed Hoste EA, Lameire NH, Vanholder RC, Benoit DD, Decruyenaere JM, Colardyn FA (2003) Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol 14(4):1022–1030CrossRefPubMed
Metadaten
Titel
Contrast-induced nephropathy in patients with active cancer undergoing contrast-enhanced computed tomography
verfasst von
Seok-In Hong
Shin Ahn
Yoon-Seon Lee
Won Young Kim
Kyung Soo Lim
Jae Ho Lee
Jae-Lyun Lee
Publikationsdatum
01.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 3/2016
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2875-6

Weitere Artikel der Ausgabe 3/2016

Supportive Care in Cancer 3/2016 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.